The document discusses neuro-inflammation and chronic pain, and the challenges of developing new drugs to treat diseases of the nervous system. It notes that animal models often fail because human brains are uniquely different. The organization ARHD has established a program providing human nervous system specimens to researchers developing new anti-inflammatory drugs, with the goal of identifying safer and more effective treatments for conditions like chronic pain, depression, dementia and traumatic brain injury.

1. ISSUE 1 | VOLUME 1 | YEAR 2016
Neuro-Inflammation
ARAHD
ADVANCE RESEARCH & HUMAN DE-
VELOPMENT LLC
10360 SW 186 ST
Suite# 1817
Miami, Fl 33197
305.726.6202 (office phone)
Web: ARAHD.COM
The sensation of pain has a very
important protective function, al-
lowing us to avoid danger or pro-
tect one area that may be injured.
However, when the nerve fibers
that carry the pain sensation be-
come injured themselves or dam-
aged by a state of chronic inflam-
mation, the pain signals may be-
come abnormally hyper-activated
and we experience constant pain.
The exact mechanism of these
conditions is probably unique to
humans and scientists in medical
research laboratories are now us-
ing small samples of the human
pain fibers to study this phenome-
non and find new drugs that can
reduce or block this abnormal
nerve activity.
The development of new medicines, across
all diseases, is an extremely challenging
activity that has to balance the need for po-
tent and effective actions with the require-
ment that such treatments be safe and de-
void of serious side effects. While in many
areas of research the medical field has
made tremendous progress over the last
several decades, the diseases of the nerv-
ous system continue to remain the most
challenging. From chronic neuropathic pain,
to neurodegenerative diseases like Parkin-
son’s and Alzheimer’s disease, the pharma-
ceutical industry has not been able to gener-
ate safe and effective treatments, in spite of
very large investments in research and drug
discovery. It is becoming more and more
apparent that one of reasons for the failure
to generate new drug for diseases of the
nervous system is that the industry almost
always uses animal models to discover new
medicines. The problem with this approach
is that if the difference between animals and
humans is too large, there is a very high
possibility that drugs that work in rats or
dogs may be completely ineffective in hu-
mans or may actually be toxic. Not surpris-
ingly, the human brain and nervous system
are quite unique and, in fact, are what distin-
guishes us the most from animals. It is
therefore not surprising that has been so
difficult to find cures for the diseases of the
human nervous system while working on
animals. It is for these reasons that ARHD
has established a program for making hu-
man nervous system specimens available to
researchers in academia as well as pharma-
ceutical companies.
Many diseases of the nervous
system, from depression to de-
mentia and traumatic brain injury,
involve an abnormal response of
the immune system of the brain.
This creates an exaggerated state
of inflammation in the brain which
can lead to the loss of neurons,
the principal building blocks of the
brain. The medical research com-
panies that are collaborating with
ARAHD, now have the possibility
of studying the cells of the im-
mune system of the brain in order
to identify new drugs capable of
acting as inhibitors of inflamma-
tion. These new drugs, once prov-
en to be active and safe on hu-
man brains, will become the new
treatments for many diseases, for
which no therapies are available
today.
CONTACT A REPRESENTATIVE TODAY:
Advancing the discovery
of new medications
for treating diseases of
the nervous system
Chronic Pain